Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity

Sirtuin-3 (SIRT3) Protein Attenuates Doxorubicin-induced Oxidative Stress and Improves Mitochondrial Respiration in H9c2 Cardiomyocytes

(2015) Kyle G. Cheung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Insulin Protects Cardiac Myocytes from Doxorubicin Toxicity by Sp1-Mediated Transactivation of Survivin

(2015) Beom Seob Lee et al.   PLoS One

Emergence of Hydrogen Sulfide as an Endogenous Gaseous Signaling Molecule in Cardiovascular Disease

(2014) David J. Polhemus et al.   CIRCULATION RESEARCH

S-Propargyl-Cysteine, a Novel Water-Soluble Modulator of Endogenous Hydrogen Sulfide, Promotes Angiogenesis Through Activation of Signal Transducer and Activator of Transcription 3

(2013) Juntao Kan et al.   ANTIOXIDANTS & REDOX SIGNALING

Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer

(2013) S. Xu et al.   MOLECULAR CANCER THERAPEUTICS

S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuated tumor necrosis factor-?-induced inflammatory signaling and dysfunction in endothelial cells

(2012) Li Long Pan et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Tirapazamine-Doxorubicin Interaction Referring to Heart Oxidative Stress and Ca2+Balance Protein Levels

(2012) Justyna Sliwinska et al.   Oxidative Medicine and Cellular Longevity

Mitochondrial STAT3 Activation and Cardioprotection by Ischemic Postconditioning in Pigs With Regional Myocardial Ischemia/Reperfusion

(2011) Gerd Heusch et al.   CIRCULATION RESEARCH

A murine model of inducible, cardiac-specific deletion of STAT3: Its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning

(2011) Roberto Bolli et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress

(2011) Xiu-Yu Wang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Doxorubicin Induces Apoptosis in H9c2 Cardiomyocytes: Role of Overexpressed Eukaryotic Translation Initiation Factor 5A

(2010) Xiao Tan et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells

(2010) Yan Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium

(2010) David Montaigne et al.   MITOCHONDRION

Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation

(2010) Amy V. Pointon et al.   PLoS One

Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro

(2009) Partha Mukhopadhyay et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Protective Effects of Cysteine Analogues on Acute Myocardial Ischemia: Novel Modulators of Endogenous H2S Production

(2009) Qian Wang et al.   ANTIOXIDANTS & REDOX SIGNALING

Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin

(2009) Jing Zhou et al.   BIOCHEMICAL PHARMACOLOGY

Doxorubicin Cardiomyopathy

(2009) Kanu Chatterjee et al.   CARDIOLOGY

Doxorubicin: The Good, the Bad and the Ugly Effect

(2009) Cristina Carvalho et al.   CURRENT MEDICINAL CHEMISTRY

S-propargyl-cysteine Protects Both Adult Rat Hearts and Neonatal Cardiomyocytes From Ischemia/Hypoxia Injury: The Contribution of the Hydrogen Sulfide-Mediated Pathway

(2009) Qian Wang et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion

(2008) Britt N. Fuglesteg et al.   BASIC RESEARCH IN CARDIOLOGY

The myocardial JAK/STAT pathway: From protection to failure

(2008) K BOENGLER et al.   PHARMACOLOGY & THERAPEUTICS

Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy

(2007) Masayasu Esaki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY